Wang Y, Ji N, Zhang Y, Chu J, Pan C, Zhang P, et al. B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of Vγ9Vδ2 T cells in glioblastoma. J Transl Med. 2023;21:672 pubmed publisher

Yang A, Zhang Z, Chaurasiya S, Park A, Jung A, Lu J, et al. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases. J Immunother Cancer. 2023;11: pubmed publisher

Saber M. Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma. J Immunol Res. 2023;2023:4556586 pubmed publisher

Saber M. EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma. J Immunol Res. 2022;2022:7219207 pubmed publisher

Eikmans M, van der Keur C, Anholts J, Drabbels J, van Beelen E, de Sousa Lopes S, et al. Primary Trophoblast Cultures: Characterization of HLA Profiles and Immune Cell Interactions. Front Immunol. 2022;13:814019 pubmed publisher

Liang Y, Chen K, Tsai J, Cheng Y, Lee C, Kao C, et al. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. J Biomed Sci. 2021;28:75 pubmed publisher

HUBBARD J, Pyzik M, Rath T, Kozicky L, Sand K, Gandhi A, et al. FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity. J Exp Med. 2020;217: pubmed publisher

Cines D, Zaitsev S, Rauova L, Rux A, Stepanova V, Krishnaswamy S, et al. FcRn augments induction of tissue factor activity by IgG-containing immune complexes. Blood. 2020;135:2085-2093 pubmed publisher

Torres Adorno A, Vitrac H, Qi Y, Tan L, Levental K, Fan Y, et al. Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. Oncogene. 2019;38:2135-2150 pubmed publisher